IN
$1.60
+0.06
(+3.90%)
As of Oct 20, 2026, 6:42 PM EDT · cached
Price history
Inmune Bio Inc (INMB) is trading up at $1.60 (+3.90%), as of the latest quote. It operates in the Health Care sector.
Inmune Bio Inc revenue & net income history (FY2017–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $0 | $0 | — | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K |
| Growth (year over year) | — | — | — | — | +1545.5% | +106.6% | −58.6% | −91.0% | +257.1% |
| Operating income | −$981.5K | −$12.4M | −$7.76M | −$12.2M | −$29.2M | −$26.0M | −$29.7M | −$42.6M | −$47.4M |
| Operating margin | — | — | — | −111163.6% | −16106.6% | −6938.8% | −19187.7% | −304535.7% | −94766.0% |
| Net income | −$831.5K | −$12.4M | −$7.68M | −$12.1M | −$30.3M | −$27.3M | −$30.0M | −$42.1M | −$45.9M |
| Net margin | — | — | — | −109990.9% | −16762.4% | −7299.2% | −19360.0% | −300585.7% | −91866.0% |
| EPS (diluted) | −$0.13 | −$1.43 | −$0.75 | −$1.01 | −$1.88 | −$1.52 | −$1.67 | −$2.11 | −$1.86 |
| Balance sheet | |||||||||
| Cash and equivalents | $1.37M | $186.2K | $7.00M | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M |
| Total assets | $18.4M | $17.4M | $24.5M | $40.7M | $99.9M | $81.8M | $57.0M | $39.6M | $32.4M |
| Total liabilities | $309.7K | $823.8K | $860.5K | $1.90M | $19.7M | $21.7M | $18.9M | $7.46M | $8.83M |
| Long-term debt | — | — | — | — | $15.0M | $9.70M | — | $15.0M | — |
| Shareholders' equity | $18.1M | $16.5M | $23.6M | $38.8M | $80.2M | $60.1M | $37.3M | $32.1M | $23.5M |
| Cash flow | |||||||||
| Operating cash flow | −$761.8K | −$2.06M | −$5.38M | −$8.94M | −$28.5M | −$22.7M | −$12.0M | −$33.4M | −$22.6M |
| Capital expenditure | — | — | — | — | — | — | — | — | $1.04M |
| Free cash flow | — | — | — | — | — | — | — | — | −$23.6M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $50.0K | $0 | $0 | — | — | — |
| Growth (year over year) | −100.0% | — | +257.1% | — | — | — | — | — |
| Operating income | −$12.3M | — | −$9.90M | −$24.6M | −$7.43M | — | −$5.81M | −$1.48M |
| Operating margin | — | — | −19810.0% | — | — | — | — | — |
| Net income | −$12.1M | — | −$9.74M | −$24.5M | −$6.47M | — | −$5.41M | −$1.27M |
| Net margin | — | — | −19478.0% | — | — | — | — | — |
| EPS (diluted) | −$0.60 | — | −$0.43 | −$1.05 | −$0.24 | — | −$0.20 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $33.6M | $20.9M | $19.3M | $33.4M | $27.7M | $24.8M | $21.4M | $18.4M |
| Total assets | $52.8M | $39.6M | $37.8M | $37.7M | $33.4M | $32.4M | $25.8M | $26.8M |
| Total liabilities | $14.1M | $7.46M | $8.13M | $8.82M | $7.98M | $8.83M | $6.19M | $6.48M |
| Long-term debt | — | $15.0M | $15.0M | $15.0M | — | — | — | — |
| Shareholders' equity | $38.7M | $32.1M | $29.7M | $28.9M | $25.4M | $23.5M | $19.6M | $20.4M |
| Cash flow | ||||||||
| Operating cash flow | −$6.99M | — | −$6.82M | −$7.38M | −$5.44M | — | −$3.40M | −$3.17M |
| Capital expenditure | — | — | — | — | $193.0K | — | — | — |
| Free cash flow | — | — | — | — | −$5.63M | — | — | — |
From Inmune Bio Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Inmune Bio Inc
- Headquarters
- Boca Raton, Florida From SEC filings, Oct 2026
Recent News (3)
-
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™ BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum compu…
-
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™ Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks …
-
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained th…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International